Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Brain Behav ; 14(2): e3444, 2024 02.
Article in English | MEDLINE | ID: mdl-38409930

ABSTRACT

BACKGROUND: Morin is a flavonoid found in many edible fruits. The hippocampus and entorhinal cortex play crucial roles in memory formation and consolidation. This study aimed to characterize the effect of morin on recognition and space memory in healthy C57BL/6 adult mice and explore the underlying molecular mechanism. METHODS: Morin was administered i.p. at 1, 2.5, and 5 mg/kg/24 h for 10 days. The Morris water maze (MWM), novel object recognition, novel context recognition, and tasks were conducted 1 day after the last administration. The mice's brains underwent histological characterization, and their protein expression was examined using immunohistochemistry and Western blot techniques. RESULTS: In the MWM and novel object recognition tests, mice treated with 1 mg/kg of morin exhibited a significant recognition index increase compared to the control group. Besides, they demonstrated faster memory acquisition during MWM training. Additionally, the expression of pro-brain-derived neurotrophic factor (BDNF), BDNF, and postsynaptic density protein 95 proteins in the hippocampus of treated mice showed a significant increase. In the entorhinal cortex, only the pro-BDNF increased. Morin-treated mice exhibited a significant increase in the hippocampus's number and length of dendrites. CONCLUSION: This study shows that morin improves recognition memory and spatial memory in healthy adult mice.


Subject(s)
Brain-Derived Neurotrophic Factor , Flavones , Flavonoids , Mice , Animals , Brain-Derived Neurotrophic Factor/metabolism , Maze Learning , Mice, Inbred C57BL , Flavonoids/pharmacology , Flavonoids/metabolism , Hippocampus/metabolism , Spatial Memory
2.
J Biomol Struct Dyn ; 41(22): 13138-13153, 2023.
Article in English | MEDLINE | ID: mdl-36705144

ABSTRACT

The aryl hydrocarbon receptor (AhR) has broad biological functions when its ligands activate it; the non-binding interactions with AhR have not been fully elucidated due to the absence of a complete tridimensional (3D) structure. Therefore, utilization of the whole 3D structure from Homo sapiens AhR by in silico studies will allow us to better study and analyze the binding mode of its full and partial agonists, and antagonists, as well as its interaction with the HSP90 chaperone. The 3D AhR structure was obtained from I-TASSER and subjected to molecular dynamics (MD) simulations to obtain different structural conformations and determine the most populated AhR conformer by clustering analyses. The AhR-3D structures selected from MD simulations and those from clustering analyses were used to achieve docking studies with some of its ligands and protein-protein docking with HSP90. Once the AhR-3D structure was built, its Ramachandran maps and energy showed a well-qualified 3D model. MD simulations showed that the per-Arnt-Sim homology (PAS) PAS A, PAS B, and Q domains underwent conformational changes, identifying the conformation when agonists were binding also, and HSP90 was binding near the PAS A, PAS B, and Q domains. However, when antagonists are binding, HSP90 does not bind near the PAS A, PAS B, and Q domains. These studies show that the complex agonist-AhR-HSP90 can be formed, but this complex is not formed when an antagonist is binding. Knowing the conformations when the ligands bind to AHR and the behavior of HSP90 allows for an understanding of its activity.Communicated by Ramaswamy H. Sarma.


Subject(s)
Molecular Dynamics Simulation , Receptors, Aryl Hydrocarbon , Humans , Receptors, Aryl Hydrocarbon/chemistry , Ligands , Protein Binding
3.
Cell Mol Neurobiol ; 43(4): 1595-1618, 2023 May.
Article in English | MEDLINE | ID: mdl-35953741

ABSTRACT

Fiber intake is associated with a lower risk for Alzheimer´s disease (AD) in older adults. Intake of plant-based diets rich in soluble fiber promotes the production of short-chain fatty acids (SCFAs: butyrate, acetate, propionate) by gut bacteria. Butyrate administration has antiinflammatory actions, but propionate promotes neuroinflammation. In AD patients, gut microbiota dysbiosis is a common feature even in the prodromal stages of the disease. It is unclear whether the neuroprotective effects of fiber intake rely on gut microbiota modifications and specific actions of SCFAs in brain cells. Here, we show that restoration of the gut microbiota dysbiosis through the intake of soluble fiber resulted in lower propionate and higher butyrate production, reduced astrocyte activation and improved cognitive function in 6-month-old male APP/PS1 mice. The neuroprotective effects were lost in antibiotic-treated mice. Moreover, propionate promoted higher glycolysis and mitochondrial respiration in astrocytes, while butyrate induced a more quiescent metabolism. Therefore, fiber intake neuroprotective action depends on the modulation of butyrate/propionate production by gut bacteria. Our data further support and provide a mechanism to explain the beneficial effects of dietary interventions rich in soluble fiber to prevent dementia and AD. Fiber intake restored the concentration of propionate and butyrate by modulating the composition of gut microbiota in male transgenic (Tg) mice with Alzheimer´s disease. Gut dysbiosis was associated with intestinal damage and high propionate levels in control diet fed-Tg mice. Fiber-rich diet restored intestinal integrity and promoted the abundance of butyrate-producing bacteria. Butyrate concentration was associated with better cognitive performance in fiber-fed Tg mice. A fiber-rich diet may prevent the development of a dysbiotic microbiome and the related cognitive dysfunction in people at risk of developing Alzheimer´s disease.


Subject(s)
Alzheimer Disease , Cognitive Dysfunction , Gastrointestinal Microbiome , Neuroprotective Agents , Mice , Animals , Propionates/pharmacology , Alzheimer Disease/metabolism , Gastrointestinal Microbiome/physiology , Dysbiosis , Neuroprotective Agents/pharmacology , Butyrates/pharmacology , Butyrates/metabolism , Dietary Fiber/pharmacology , Mice, Transgenic , Cognitive Dysfunction/prevention & control
4.
Molecules ; 25(21)2020 Oct 29.
Article in English | MEDLINE | ID: mdl-33137907

ABSTRACT

Alzheimer's disease (AD) is a neurodegenerative disease with no cure nowadays; there is no treatment either to prevent or to stop its progression. In vitro studies suggested that tert-butyl-(4-hydroxy-3-((3-(2-methylpiperidin-yl)propyl)carbamoyl)phenyl) carbamate named the M4 compound can act as both ß-secretase and an acetylcholinesterase inhibitor, preventing the amyloid beta peptide (Aß) aggregation and the formation of fibrils (fAß) from Aß1-42. This work first aimed to assess in in vitro studies to see whether the death of astrocyte cells promoted by Aß1-42 could be prevented. Second, our work investigated the ability of the M4 compound to inhibit amyloidogenesis using an in vivo model after scopolamine administration. The results showed that M4 possesses a moderate protective effect in astrocytes against Aß1-42 due to a reduction in the TNF-α and free radicals observed in cell cultures. In the in vivo studies, however, no significant effect of M4 was observed in comparison with a galantamine model employed in rats, in which case this outcome was attributed to the bioavailability of M4 in the brain of the rats.


Subject(s)
Alzheimer Disease , Amyloid beta-Peptides/metabolism , Astrocytes/metabolism , Carbamates , Neuroprotective Agents , Peptide Fragments/metabolism , Scopolamine/adverse effects , Alzheimer Disease/chemically induced , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Alzheimer Disease/prevention & control , Animals , Astrocytes/pathology , Carbamates/chemistry , Carbamates/pharmacology , Disease Models, Animal , Humans , Neuroprotective Agents/chemistry , Neuroprotective Agents/pharmacology , Rats , Scopolamine/pharmacology
5.
Int J Mol Sci ; 21(6)2020 Mar 14.
Article in English | MEDLINE | ID: mdl-32183254

ABSTRACT

One of the characteristics of the cerebral aging process is the presence of chronic inflammation through glial cells, which is particularly significant in neurodegeneration. On the other hand, it has been demonstrated that the aryl hydrocarbon receptor (AHR) participates in the inflammatory response. Currently, evidence in animal models shows that the hallmarks of aging are associated with changes in the AHR levels. However, there is no information concerning the behavior and participation of AHR in the human aging brain or in Alzheimer's disease (AD). We evaluated the expression of AHR in human hippocampal post-mortem tissue and its association with reactive astrocytes by immunohistochemistry. Besides this, we analyzed through ELISA the AHR levels in blood serum from young and elder participants, and from AD patients. The levels of AHR and glial fibrillar acid protein were higher in elder than in young post-mortem brain samples. AHR was localized mainly in the cytosol of astrocytes and displayed a pattern that resembles extracellular vesicles; this latter feature was more conspicuous in AD subjects. We found higher serum levels of AHR in AD patients than in the other participants. These results suggest that AHR participates in the aging process, and probably in the development of neurodegenerative diseases like AD.


Subject(s)
Alzheimer Disease/metabolism , Astrocytes/metabolism , Basic Helix-Loop-Helix Transcription Factors/analysis , Basic Helix-Loop-Helix Transcription Factors/blood , Hippocampus/metabolism , Receptors, Aryl Hydrocarbon/analysis , Receptors, Aryl Hydrocarbon/blood , Adolescent , Adult , Aged , Aged, 80 and over , Aging/physiology , Animals , Enzyme-Linked Immunosorbent Assay , Extracellular Vesicles/metabolism , Female , Glial Fibrillary Acidic Protein/analysis , Humans , Immunohistochemistry , Male , Mice , Mice, Inbred C57BL , Middle Aged , Young Adult
6.
J Mol Neurosci ; 70(2): 180-193, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31768942

ABSTRACT

Alzheimer's disease (AD) is one of the most complicated neurodegenerative diseases, and several hypotheses have been associated with its development and progression, such as those involving glucose hypometabolism, the cholinergic system, calcium imbalance, inflammation, oxidative imbalance, microtubule instability, and the amyloid cascade, several of which are related to oxidative stress (free radical generation), which contributes to neuronal death. Therefore, several efforts have been made to establish a sporadic AD model that takes into account these hypotheses. One model that replicates the increase in amyloid beta (Aß) and oxidative stress in vivo is the scopolamine model. In the present work, the chronic administration (6 weeks) of scopolamine was used to analyze the neuroprotective effects of apocynin and galantamine. The results showed that scopolamine induced cognitive impairment, which was evaluated 24 h after the final dose was administered. In addition, after scopolamine administration, the Aß and superoxide anion levels were increased, and NADPH oxidase 2 (NOX2), nuclear factor erythroid 2-related factor 2 (Nrf2), and nuclear factor kappa B (NFkB) genes were overexpressed. These effects were not observed when either apocynin or galantamine was administered during the last 3 weeks of scopolamine treatment, and although the results from both molecules were related to lower Aß production and, consequently, lower superoxide anion production, they were likely realized through different pathways. That is, both apocynin and galantamine diminished NADPH oxidase expression, but their effects on transcription factor expression differed. Moreover, experiments in silico showed that galantamine did not interact with the active site of beta secretase, whereas diapocynin, an apocynin metabolite, interacted with the beta-site APP-cleaving enzyme (BACE1) at the catalytic site.


Subject(s)
Acetophenones/therapeutic use , Alzheimer Disease/drug therapy , Galantamine/therapeutic use , Neuroprotective Agents/therapeutic use , Acetophenones/pharmacology , Alzheimer Disease/etiology , Amyloid beta-Peptides/metabolism , Animals , Cognition , Galantamine/pharmacology , Hippocampus/drug effects , Hippocampus/metabolism , Male , NADPH Oxidase 2/genetics , NADPH Oxidase 2/metabolism , NF-kappa B/genetics , NF-kappa B/metabolism , Neuroprotective Agents/pharmacology , Oxidative Stress , Rats , Rats, Wistar , Scopolamine/toxicity
7.
Cent Nerv Syst Agents Med Chem ; 10(4): 269-77, 2010 Dec 01.
Article in English | MEDLINE | ID: mdl-20868360

ABSTRACT

Polyphenols are the most abundant antioxidants in diet. These can be found in fruits, vegetables, beverages (tea, wine, juices, etc.), plants and some herbs. These compounds are capable of protecting neuronal cells in different in vivo and in vitro models through diverse intracellular targets. The focus of this review is aimed at presenting the role of some polyphenols on the molecular mechanism involve in neuroprotection through different biological processes like oxidative stress, excitotoxicity, apoptotic neuronal death, regulation of the kinase signal cascade and modulation of Ubiquitin-Proteasome pathway. The study of the molecular mechanisms involved in neuroprotection and the molecular targets of natural polyphenols are important in the discovery of a valuable tool for new and more advanced therapy in neurodegenerative diseases.


Subject(s)
Flavonoids/pharmacology , Neuroprotective Agents , Phenols/pharmacology , Animals , Calcium/metabolism , Cell Death/drug effects , Humans , Mitochondria/drug effects , Neurons/drug effects , Oxidative Stress/drug effects , Peptide Hydrolases/metabolism , Polyphenols , Proteasome Endopeptidase Complex/physiology , Ubiquitin/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...